加用舒利迭对哮喘合并COPD患者FEV、PEF水平及T淋巴细胞分化的影响分析
|
摘要
目的 :研究并分析加用舒利迭对哮喘合并慢性阻塞性肺疾病(COPD)患者FEV、PEF水平及T淋巴细胞分化的影响。方法 :选取2015年2月～2016年2月我院收治的哮喘合并COPD患者84例。根据随机数字表法分成观察组与对照组,每组42例。对照组患者予以抗胆碱药物、抗生素、镇咳剂以及茶碱类药物行常规治疗。观察组患者则在对照组的基础上加用舒利迭吸入治疗。所有患者均予以连续12周的治疗,并进行为期1年的随访。分别对比治疗前后患者FEV、PEF水平变化情况,T淋巴细胞分化情况,血气指标变化情况,急性加重发作次数与发作间隔时间变化情况。结果 :治疗后观察组患者PEF水平为(251.2±75.6)L/S,显著高于对照组的(187.8±45.6)L/S。治疗后观察组患者IL-1水平为(124.8±8.5),显著高于对照组的(58.2±8.6),而IFN水平为(125.2±8.1),显著低于对照组的(189.8±12.3)。治疗后观察组患者PaCO2水平为(54.3±10.3)mmHg,显著低于对照组的(61.7±13.7)mmHg,而PaO2水平为(88.2±28.4)mmHg,显著高于对照组的(73.3±23.0)mmHg。治疗后观察组急性加重发作次数为(3.4±0.9)次,显著低于对照组的(10.7±2.3)次,而发作间隔时间为(71.5±6.7)d,显著高于对照组的(43.5±6.0)。结论 :加用舒利迭治疗哮喘合并COPD可显著改善患者肺功能,同时改善患者T淋巴细胞的分化情况,有利于缓解急性加重病症,值得临床推广应用。
Objective To study and use nimesulide idea on asthma combined chronic obstructive pulmonary disease(COPD patients FEV, PEF level, and the influence of T lymphocyte differentiation and analyzed. Methods Selected from February2015 to February 2016, 84 cases of asthma in our hospital with COPD patients. According to random number table method was divided into observation group and control group, 42 cases in each group. The control group patients were given choline medicines, antibiotics, antitussive agent and the conventional treatment of theophylline drugs. On the basis of the observation group of patients were in the control group used nimesulide overlapping inhalation therapy. All the patients were treated for 12 consecutive weeks, and for a 1 year follow-up. Compared respectively before and after treatment in patients with FEV, PEF level, the changes of T lymphocyte differentiation, blood gas index changes, acute aggravating attack frequency and time interval. Results The observation group of patients after treatment of PEF level for(251.2±75.6) L/S, significantly higher than that of control group(187.8±45.6) L/S. IL-1 level for the observation group patients after treatment(124.8±8.5), significantly higher than that of control group(58.2±8.6), and IFN level(125.2±8.1), significantly lower than the control group(189.8 ±12.3). Observation group of patients after treatment PaCO2 level(54.3±10.3) mmHg, significantly lower than in the control group(61.7±13.7) mmHg, PaO2 level for(88.2±28.4) mmHg, significantly higher than that of control group(73.3±23.0) mmHg. Observation group after treatment of acute aggravation episodes(3.4±0.9), significantly lower than in the control group(10.7±2.3), and the attack time interval for(71.5±6.7) d, significantly higher than that of control group(43.5±6.0). Conclusion Treatment with nimesulide wad merger can significantly improve lung function in patients with COPD and asthma patients at the same time improve T lymphocyte differentiation condition, alleviates acute aggravating illness, worthy of clinical popularization and application.
Objective To study and use nimesulide idea on asthma combined chronic obstructive pulmonary disease(COPD patients FEV, PEF level, and the influence of T lymphocyte differentiation and analyzed. Methods Selected from February2015 to February 2016, 84 cases of asthma in our hospital with COPD patients. According to random number table method was divided into observation group and control group, 42 cases in each group. The control group patients were given choline medicines, antibiotics, antitussive agent and the conventional treatment of theophylline drugs. On the basis of the observation group of patients were in the control group used nimesulide overlapping inhalation therapy. All the patients were treated for 12 consecutive weeks, and for a 1 year follow-up. Compared respectively before and after treatment in patients with FEV, PEF level, the changes of T lymphocyte differentiation, blood gas index changes, acute aggravating attack frequency and time interval. Results The observation group of patients after treatment of PEF level for(251.2±75.6) L/S, significantly higher than that of control group(187.8±45.6) L/S. IL-1 level for the observation group patients after treatment(124.8±8.5), significantly higher than that of control group(58.2±8.6), and IFN level(125.2±8.1), significantly lower than the control group(189.8 ±12.3). Observation group of patients after treatment PaCO2 level(54.3±10.3) mmHg, significantly lower than in the control group(61.7±13.7) mmHg, PaO2 level for(88.2±28.4) mmHg, significantly higher than that of control group(73.3±23.0) mmHg. Observation group after treatment of acute aggravation episodes(3.4±0.9), significantly lower than in the control group(10.7±2.3), and the attack time interval for(71.5±6.7) d, significantly higher than that of control group(43.5±6.0). Conclusion Treatment with nimesulide wad merger can significantly improve lung function in patients with COPD and asthma patients at the same time improve T lymphocyte differentiation condition, alleviates acute aggravating illness, worthy of clinical popularization and application.
引文
[1]Kim J, Kim WJ, Lee CH, et al. Which bronchodilator reversibility criteria can predict severe acute exacerbation inchronic obstructive pulmonary diseasepatients[J]. Respir Res, 2017, 18(1):107-108.
[2]王嵘,和晓华,杨眉,等.沙美特罗替卡松联合噻托溴铵吸入对支气管哮喘合并慢性阻塞性肺疾病患者肺功能的改善作用[J].中国基层医药, 2014, 21(23):3563-3565.
[3]韩海东,焦素芳,彭文革,等.气管哮喘合并慢性阻塞性肺疾病利用布地奈德联合大剂量氟替卡松治疗的疗效分析[J].河北医药,2014, 36(10):1473-1475.
[4]楚长城.复方异丙托溴铵合并沙美特罗治疗支气管哮喘合并COPD稳定期的临床价值探讨[J].中国医药指南, 2017, 15(8):181-182.
[5]蔡明文,谭琳. VEGF、IL-13、IL-17对慢性阻塞性肺疾病合并支气管哮喘的鉴别诊断意义[J].临床和实验医学杂志, 2015, 14(23):1941-1944.
[6]窦丽阳,刘颖,陈颖,等.老年支气管哮喘-慢性阻塞性肺病重叠综合征的临床研究[J].北京医学, 2016, 38(10):1009-1013.
[7]张希,崔珺,马咏梅,等.诱导痰中血管内皮生长因子、细胞因子对慢性阻塞性肺疾病合并哮喘诊断的临床意义[J].临床肺科杂志,2017, 22(6):1043-1046.
[8]潘春香,胡祥坤,孙如坤,等. COPD与支气管哮喘合并COPD患者肺通气功能、气道激发试验及疗效观察[J].中国实用医刊, 2016,43(5):111-112.
[9]邵剑骏,莫伟强,余晓燕,等.噻托溴铵联合沙美特罗替卡松吸入治疗中重度支气管哮喘合并慢性阻塞性肺疾病的临床疗效分析[J].国际呼吸杂志, 2012, 32(11):801-803.
[10]饶敏,李娟.舒利迭与吸入性糖皮质激素联合孟鲁司特钠治疗儿童中度持续性哮喘的疗效对比研究[J].湖南师范大学学报(医学版), 2016, 13(3):123-126.
[11]林娟.噻托溴铵联合大剂量舒利迭治疗重度支气管哮喘合并慢性阻塞性肺疾病的临床效果分析[J].中外医学研究, 2016, 14(36):8-10.
[12]王敏.舒利迭对哮喘合并COPD患者肺功能及T淋巴细胞分化的影响[J].河南职工医学院学报, 2012, 24(6):739-740.
[13]陈晓青.噻托溴铵联合大剂量舒利迭治疗重度支气管哮喘合并慢性阻塞性疾病的疗效观察[J].中国医院药学杂志, 2013, 33(13):1075-1078.
[14]龙瑜琴,程晓明.噻托溴铵联合大剂量舒利迭治疗重度支气管哮喘合并慢性阻塞性肺疾病的效果观察[J].中国医药导报, 2013,10(2):166-168.
[15]赵洪.噻托溴铵联合大剂量舒利迭治疗重度支气管哮喘合并慢性阻塞性肺疾病的疗效及安全性[J].安徽医药, 2015, 19(8):1593-1594.
[2]王嵘,和晓华,杨眉,等.沙美特罗替卡松联合噻托溴铵吸入对支气管哮喘合并慢性阻塞性肺疾病患者肺功能的改善作用[J].中国基层医药, 2014, 21(23):3563-3565.
[3]韩海东,焦素芳,彭文革,等.气管哮喘合并慢性阻塞性肺疾病利用布地奈德联合大剂量氟替卡松治疗的疗效分析[J].河北医药,2014, 36(10):1473-1475.
[4]楚长城.复方异丙托溴铵合并沙美特罗治疗支气管哮喘合并COPD稳定期的临床价值探讨[J].中国医药指南, 2017, 15(8):181-182.
[5]蔡明文,谭琳. VEGF、IL-13、IL-17对慢性阻塞性肺疾病合并支气管哮喘的鉴别诊断意义[J].临床和实验医学杂志, 2015, 14(23):1941-1944.
[6]窦丽阳,刘颖,陈颖,等.老年支气管哮喘-慢性阻塞性肺病重叠综合征的临床研究[J].北京医学, 2016, 38(10):1009-1013.
[7]张希,崔珺,马咏梅,等.诱导痰中血管内皮生长因子、细胞因子对慢性阻塞性肺疾病合并哮喘诊断的临床意义[J].临床肺科杂志,2017, 22(6):1043-1046.
[8]潘春香,胡祥坤,孙如坤,等. COPD与支气管哮喘合并COPD患者肺通气功能、气道激发试验及疗效观察[J].中国实用医刊, 2016,43(5):111-112.
[9]邵剑骏,莫伟强,余晓燕,等.噻托溴铵联合沙美特罗替卡松吸入治疗中重度支气管哮喘合并慢性阻塞性肺疾病的临床疗效分析[J].国际呼吸杂志, 2012, 32(11):801-803.
[10]饶敏,李娟.舒利迭与吸入性糖皮质激素联合孟鲁司特钠治疗儿童中度持续性哮喘的疗效对比研究[J].湖南师范大学学报(医学版), 2016, 13(3):123-126.
[11]林娟.噻托溴铵联合大剂量舒利迭治疗重度支气管哮喘合并慢性阻塞性肺疾病的临床效果分析[J].中外医学研究, 2016, 14(36):8-10.
[12]王敏.舒利迭对哮喘合并COPD患者肺功能及T淋巴细胞分化的影响[J].河南职工医学院学报, 2012, 24(6):739-740.
[13]陈晓青.噻托溴铵联合大剂量舒利迭治疗重度支气管哮喘合并慢性阻塞性疾病的疗效观察[J].中国医院药学杂志, 2013, 33(13):1075-1078.
[14]龙瑜琴,程晓明.噻托溴铵联合大剂量舒利迭治疗重度支气管哮喘合并慢性阻塞性肺疾病的效果观察[J].中国医药导报, 2013,10(2):166-168.
[15]赵洪.噻托溴铵联合大剂量舒利迭治疗重度支气管哮喘合并慢性阻塞性肺疾病的疗效及安全性[J].安徽医药, 2015, 19(8):1593-1594.